Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Gossamer Bio (GOSS) EBIT (2022 - 2025)

Historic EBIT for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$49.1 million.

  • Gossamer Bio's EBIT fell 4479.79% to -$49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$160.8 million, marking a year-over-year decrease of 12084.79%. This contributed to the annual value of -$59.9 million for FY2024, which is 6739.26% up from last year.
  • Gossamer Bio's EBIT amounted to -$49.1 million in Q3 2025, which was down 4479.79% from -$38.8 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's EBIT ranged from a high of $52.1 million in Q2 2024 and a low of -$56.0 million during Q3 2022
  • Moreover, its 4-year median value for EBIT was -$46.3 million (2023), whereas its average is -$39.1 million.
  • As far as peak fluctuations go, Gossamer Bio's EBIT surged by 21249.89% in 2024, and later crashed by 17442.36% in 2025.
  • Gossamer Bio's EBIT (Quarter) stood at -$54.4 million in 2022, then rose by 9.81% to -$49.0 million in 2023, then increased by 26.31% to -$36.1 million in 2024, then plummeted by 35.94% to -$49.1 million in 2025.
  • Its last three reported values are -$49.1 million in Q3 2025, -$38.8 million for Q2 2025, and -$36.8 million during Q1 2025.